Aptargroup Stock Price, News & Analysis

Aptar Pharma (NYSE:ATR) has announced a significant sustainability milestone with its Freepod® nasal spray pump, used in Haleon's Otrivin® brand, now being manufactured with 52% bio-based feedstock. This marks the first Aptar delivery system using such materials to be commercialized globally.

The innovative solution features an ISCC Plus certified manufacturing process, with the bottle produced using a mass balance approach equivalent to 100% bio-based content. Combined, the pump and bottle components achieve 60% circular material content for the complete nasal spray device. The manufacturing site in Mezzovico, Switzerland, maintains ISCC PLUS certification, ensuring complete material traceability.

This development supports Haleon's sustainability goals of reducing virgin petroleum-based plastic use by 10% by 2025 and by a third by 2030, compared to 2022 levels.

AptarGroup (NYSE:ATR) announced that its nasal drug delivery system was successfully used in a groundbreaking Wake Forest University School of Medicine brain imaging study. The research validated that intranasal insulin effectively reaches 11 key brain regions associated with memory and cognition in older adults, particularly relevant for Alzheimer's treatment.

The study involved 16 older adults (average age 72), including seven cognitively normal individuals and nine with mild cognitive impairment (MCI). Key findings revealed that cognitively normal participants showed higher uptake compared to those with MCI, and women's insulin uptake correlated with cardiovascular health factors. The procedure was well-tolerated, with only two participants reporting mild, temporary headaches.

Aptar Pharma (NYSE:ATR) has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings. The strategic acquisition includes an FDA-inspected facility in Boonton, New Jersey, equipped with cGMP cleanrooms, high-potency API suites, and biologics capabilities.

The acquisition strengthens Aptar's early-stage drug development support, particularly for Phase 1 and 2 clinical trials, focusing on orally inhaled nasal drug products (OINDPs). The facility's capabilities align with Aptar's drug delivery solutions portfolio and will help address growing market demand for agile, high-quality cGMP clinical trial material supply services.

AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has declared a quarterly cash dividend of $0.45 per share. The dividend will be paid on August 14, 2025 to stockholders of record as of July 24, 2025.

Additionally, the company announced it will hold a conference call on August 1, 2025 at 8:00 a.m. Central Time to discuss Q2 2025 results. The call will be available via webcast on Aptar's Investors page.

AptarGroup (NYSE:ATR) has unveiled a groundbreaking dual-active material science technology that simultaneously controls moisture and oxygen for pharmaceutical products. This innovative solution extends their 3-Phase Activ-Polymer™ technology to protect sensitive oral solid dose drugs, medical devices, and delivery systems.

The technology represents a significant advancement in pharmaceutical protection, particularly beneficial for GLP-1 medications and various medical devices. It can be customized for different product formats and development stages while helping companies meet ICH stability requirements. Aptar also offers complementary elastomeric components for GLP-1 drug products and integrated digital patient services.

AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing and dispensing technologies, has been recognized as one of TIME's World's Most Sustainable Companies 2025, ranking 244 out of 500 global companies. This marks their second consecutive year on the list.

The company has demonstrated significant sustainability achievements, including maintaining a Platinum level rating from EcoVadis for five consecutive years, placing them in the top 1% of rated companies. Notable metrics include 97.5% renewable global electricity usage and 86% of operational waste avoiding landfill. Aptar has also secured renewable supply agreements in Europe and North America while partnering with organizations like the Ellen MacArthur Foundation to advance sustainability initiatives.

AptarGroup (NYSE: ATR), a leading provider of drug and consumer product dosing, dispensing and protection technologies, has announced its participation in two major investor conferences. The company's President and CEO Stephan Tanda, along with Executive Vice President and CFO Vanessa Kanu, will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3, 2025, at 9:40 a.m. ET. The following day, June 4, they will present at the Jefferies Global Healthcare Conference at 2:00 p.m. ET. Both presentations will be accessible via live audio webcast through the Investors section of Aptar's website.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing and dispensing technologies, has released its 2024 Corporate Sustainability Report. The report showcases progress across three key pillars: Care, Collaboration, and Circularity. Key achievements include: • 97.5% of electricity sourced from renewables • 86% of operational waste avoided landfill disposal • 60% of sites earned Landfill Free Certification The company partnered with organizations like Ellen MacArthur Foundation and World Business Council for Sustainable Development to advance circular solutions. Aptar's sustainability initiatives focus on increasing recycled resin content and developing recyclable, reusable, or compostable solutions across their product lines. The report, prepared under GRI Standards, received external assurance for its emissions reporting from SGS do Brasil Ltda.

AptarGroup (NYSE:ATR) reported Q1 2025 results with reported sales of $887 million, down 3% year-over-year, and net income of $79 million, a 5% decrease. Core sales remained flat while adjusted EBITDA increased 3% to $183 million. The company achieved an adjusted EBITDA margin of 20.7%, expanding 120 basis points. Adjusted EPS was $1.20, which would have shown a 5% increase excluding currency effects and tax rate changes. Notably, Pharma segment showed strength with 2% growth in proprietary drug delivery systems sales. The company returned $110 million to shareholders, including $80 million in share repurchases. By segment, Aptar Pharma's core sales grew 3%, while Beauty and Closures segments declined 3% and 2% respectively. Looking ahead, Aptar expects Q2 2025 adjusted EPS of $1.56-$1.64.